HC Wainwright & Co. Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $73
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raises the price target from $60 to $73.
August 22, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals' price target has been raised from $60 to $73 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase in the future. This, combined with the 'Buy' rating, suggests a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100